newsfilter.io

Lou DiGennaro

Showing 1–4 of 4 transcripts.

  1. Milken Institute1h 1m

    The Promise of the Cancer Moonshot

    Kathy Hudson, Anna Barker, L. Michelle Bennett, Robert Bradway, Louis DeGennaro, Isla Garraway, Lou DiGennaro, Greg Simon, Tom Caleo, Jackie Brandwin, Greg Zuckerman, Laura Kalmos Nasser, Mike Hiltik, Noah Crafts

    Following the Vice President's appointment to lead "Mission Control" and a proposed $1 billion federal funding request, the Cancer Moonshot initiative seeks to accelerate cancer research by prioritizing patient outcomes over bureaucratic processes. The program targets a structural shift from competition to collaboration through new mandates for data sharing, the launch of the Genomic Data Commons, and the implementation of patient-centric clinical trial designs. By leveraging public-private partnerships and modernizing regulatory frameworks, the initiative aims to bridge the gap between clinical trial success and real-world health equity within a 15-month timeline.

  2. Milken Institute1h 0m

    Smart on Science: How Today's Patients Are Driving Cures

    Kim McCleary, Bray Patrick Lake, Joe Selby, Mace Rothenberg, Lou DiGennaro, Tony Coles, Dr. Francis Collins

    Five healthcare leaders, including representatives from Pfizer, PCORI, and the NIH, convened to discuss the paradigm shift from paternalistic care models to active patient partnerships in drug development. The panel highlighted how the Precision Medicine Initiative, corporate adaptations like Pfizer's early patient integration, and PCORI's methodology have accelerated trial designs and improved outcomes by prioritizing patient-defined endpoints. Moving forward, the industry aims to leverage real-world data and shared governance to reduce the $2.2 billion cost of development while ensuring research addresses the specific needs and lived experiences of patients.

  3. Milken Institute1h 3m

    Impatient Patients: How Disease Organizations Are Accelerating Research

    Margaret Anderson, Lou DiGennaro, Jonathan Simons, Gordon Gunn, Deborah Black, John Walsh

    Representatives from Faster Cures and five major disease-focused nonprofits outlined how venture philanthropy and patient-led activism accelerate cures by de-risking early-stage research and navigating the "Valley of Death" between discovery and clinical application. Leaders from the Leukemia and Lymphoma Society, Prostate Cancer Foundation, and the Alpha-1 Foundation detailed strategic investments that generated massive financial leverage and established critical infrastructure, such as patient registries and rapid autopsy programs, to overcome funding gaps and accelerate trial recruitment. The panel concluded that sustainable progress requires aligning academia, industry, and regulators while empowering patients to actively define research priorities and drive policy changes for faster approvals and reimbursement.

  4. Milken Institute1h 0m

    Financing the Future of Bioscience and Pharma

    Melissa Stevens, Lou DiGennaro, Rajiv Kahl, Jody Black, Matthew Perry, Greg Simon

    Facing a critical funding gap where traditional venture capital and pharmaceutical giants avoid high-risk early-stage assets, diverse entities including the Leukemia & Lymphoma Society, the NIH, and crowdfunding platforms like Poliwag are deploying non-dilutive capital and democratized investment models to accelerate therapeutic development. These initiatives have successfully leveraged millions to generate billions in downstream deal flow, while regulatory shifts and public market mechanisms enable smaller biotechs to bridge the "valley of death" and reach patients faster. Ultimately, the event highlights a structural shift toward a continuum of care where government research, patient advocacy, and public markets converge to transform scientific discovery into viable treatments for life-threatening diseases.